AlphAIalphai — Financial news for AI agents
financialcontent.comAUG 53 min read$COLL

Collegium Pharmaceutical (COLL) Reports Earnings Tomorrow: What To Expect

Collegium Pharmaceutical (COLL) will report earnings Thursday before market open. The company previously posted $193.5M revenue, up 8.9% year over year, and beat EPS estimates but missed full-year revenue guidance. For the upcoming quarter, analysts expect revenue growth of about 7% y/y. COLL shares are below its average $53.60 analyst price target.

Original reporting
financialcontent.com
Published Aug 5, 2026, 4:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 4:23 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Collegium Pharmaceutical (COLL) Reports Earnings Tomorrow: What To Expect — source image
Source · financialcontent.com
Decision brief

The 30-second read

$COLLNeutralMed
01

Why it matters

Traders can use the stated consensus revenue growth (7% YoY) and the company’s recent pattern of rarely missing revenue estimates to frame expectations for the upcoming print, but there is no new guidance or datapoint beyond the preview.

02

Market read

A scheduled earnings preview for COLL with consensus and peer read-through, useful for positioning into the release but not a standalone new disclosure.

03

What to watch

The preview highlights missing full-year revenue guidance versus expectations, which could increase downside risk if management commentary does not clarify the outlook.

Relevance 4/10Novelty 4/10Timing: pre-market Thursday earnings release

Background

The article previews Collegium Pharmaceutical’s upcoming earnings, referencing last quarter’s revenue beat and the fact that full-year revenue guidance missed expectations.

Company-level read

Ticker impact

$COLLNeutralMedium confidence
Context

Collegium Pharmaceutical (COLL) is set to report earnings Thursday pre-market, with the article citing consensus revenue growth of 7% YoY.

Expected impact

Near-term volatility is likely around the report, but the article itself does not provide a fresh catalyst beyond the scheduled event.

Evidence & confidence

The text provides timing (Thursday before open) and expectations (7% YoY revenue growth) but no new company-specific disclosure like results, guidance, or a material update.

Market effects

Sector

Branded pharmaceuticals sentiment is framed as steady, using peer results as directional context for the segment.

Regional

No explicit regional market linkage beyond US-listed peers.

Global

No explicit global demand or regulatory linkage; focus remains on US earnings expectations.

Counterpoint

What could challenge this read

Because the article emphasizes that peers moved on their results, the market may already be positioned for a similar outcome, reducing incremental upside surprise potential for COLL.

Key entities

  • company
    Collegium Pharmaceutical

    NASDAQ-listed branded pharmaceuticals company scheduled to report earnings Thursday before market open.

  • company
    Bristol-Myers Squibb

    Peer cited as having reported Q2 revenue growth and a post-results stock move.

  • company
    Corcept

    Peer cited as having reported Q2 revenues and a post-results stock move.

Read at source← All news

Related articles

AUG 6
$COLLHighAI 9/10

Why is Collegium Pharmaceutical stock tumbling today?

Collegium Pharmaceutical shares fell about 13% in pre-open trading after it reported Q2 2026 results and cut full-year revenue guidance. Net revenues were $199.9M, up 6.3% but below analysts’ ~$201.2M-$201.4M. Adjusted EPS was $1.92 and adjusted EBITDA $113.8M. The pain portfolio faced generic competition, while JORNAY PM rose 41% to $46.1M and AZSTARYS added $12.9M.

investing.com4 min
AUG 6
$COLLHigh

COLLEGIUM PHARMACEUTICAL, INC (COLL): Results of Operations and Financial Condition

COLLEGIUM PHARMACEUTICAL, INC (COLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 coll-2026x06x30xex99x1.htm EX-99.1 Document Exhibit 99.1 Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress – Completed Acquisition of AZSTARYS ® , Strengthening ADHD Portfolio and Extending Long-Term Revenue Outlook – – Gener

SEC EDGAR 8-K7 min
MAY 27
$COLLHighAI 9/10

Why Collegium Pharmaceutical Inc. (COLL) Stock Is Gaining Attention for Its ADHD Portfolio

Collegium Pharmaceutical (NASDAQ:COLL) reported Q1 2026 results on May 7, with revenue up 9% YoY to $193.5 million, beating the Street’s $187.4 million estimate. Adjusted EPS rose to $1.76 from $1.49 and topped expectations of $1.63. The company cited strong ADHD franchise growth, including Jornay PM sales up 36% YoY, and expects Jornay PM revenue of $190–$200 million in 2026. Collegium also plans to expand its ADHD portfolio via Azstarys acquisition, expecting it to add over $50 million to H2 2

finance.yahoo.com5 min
AUG 8
$CPTMedAI 8/10

Camden Property Trust (CPT) Q2 2026 Earnings Call Transcript

Camden Property Trust (CPT) discussed its Q2 2026 earnings call, focusing on exiting its California multifamily portfolio. According to management, it sold the 19-year-old California portfolio for $1.625 billion, with trailing 12-month FFO and AFFO yields of 5.6% and 5.2%. Camden repurchased $694 million of shares and closed $645 million of acquisitions plus $195 million of awarded acquisitions, reaffirming $6.75/share FFO guidance.

yahoo.com7 min
AUG 8
$UNITMed

Uniti (UNIT) Q2 2026 Earnings Call Transcript

Uniti (UNIT) held its Q2 2026 earnings call, saying demand was strong across categories and highlighting growth in fiber revenue. The company reported total fiber revenue up 10% year over year and Fiber Infrastructure fiber revenue up 6%. Uniti raised its 2026 outlook for new fiber homes to 475,000 to 525,000 and said managed services attachment rose, with 16% of new bookings including it.

yahoo.com7 min